Briefing
Longitudinal tumor-informed ctDNA monitoring for recurrence and treatment response in melanoma.
A retrospective series of 56 people with melanoma evaluated serial tumor-informed Signatera ctDNA for recurrence and treatment response.
- Design: Evidence level 3
- Assay: Signatera